Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced Solid Tumors
NCT00940225Phase 2Completed
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2009
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of cabozantinib in breast cancer, gastric cancer (GC), gastroesophageal junction cancer, hepatocellular carcinoma (HCC), melanoma, sponsored by Exelixis, Inc.. Started Sep 2009; status: completed.
02
Drugs
cabozantinib
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction cancerhepatocellular carcinoma (HCC)melanoma
Beyond the preview
Go deeper on NCT00940225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940225.